mRNA-1273.815

BIOLOGICAL3 trials

Sponsors

ModernaTX, Inc.

Conditions

COVID-19SARS-CoV-2

Phase 2

A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants

CompletedNCT04927065

ModernaTX, Inc.SARS-CoV-2

Start: 2021-05-28End: 2023-11-17Updated: 2025-02-28

Phase 3

A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age

CompletedNCT05436834

ModernaTX, Inc.SARS-CoV-2

Start: 2022-06-21End: 2025-10-20Updated: 2025-11-26

A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19

CompletedNCT05815498

ModernaTX, Inc.COVID-19

Start: 2023-03-28End: 2025-04-12Updated: 2025-05-07

Related Papers

563. Safety and Immunogenicity of mRNA-1273.815 in COVID-19 Vaccine-Naïve Children 2 Through 4 Years of Age: Results From a Phase 3, Open-Label Trial

Open Forum Infectious Diseases2026-01-01

Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial.

2025-07-077 citations

P-102. Six-Month Safety, Durability, and Cross-Neutralization of the SARS-CoV-2 XBB.1.5-Containing Vaccine

Open Forum Infectious Diseases2025-01-29

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine

The Journal of Infectious Diseases2025-01-1010 citations

Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.

2024-03-193 citations

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results

Nature Medicine2023-08-3168 citations

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.

2023-08-2320 citations

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.

2022-10-06121 citations

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

New England Journal of Medicine2022-09-16635 citations